Pharmaceutical Continuous Manufacturing Market Report 2026

The pharmaceutical continuous manufacturing market size has grown rapidly in recent years. It will grow from $2.69 billion in 2025 to $2.97 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising drug demand volumes, need for improved production efficiency, high batch manufacturing variability, increasing cost pressures on pharma companies, early regulatory pilot approvals.

The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing adoption of pcm by big pharma, increasing investment in smart factories, demand for faster scale-up and commercialization, focus on supply chain resilience, advancements in continuous processing equipment. Major trends in the forecast period include shift from batch to end-to-end continuous production, increased adoption of modular and flexible manufacturing lines, growing focus on real-time quality assurance and control, expansion of continuous manufacturing for API production, rising regulatory support for continuous manufacturing.

The growing adoption of industrial automation is expected to drive the expansion of the pharmaceutical continuous manufacturing market in the coming years. Industrial automation involves the use of control systems, including computers and robots, to operate and manage industrial processes and machinery, thereby replacing or supporting human involvement. In pharmaceutical continuous manufacturing, industrial automation enables effective monitoring and real-time feedback control throughout continuous manufacturing processes, reducing human error and ensuring consistent product quality. For example, in September 2023, according to the World Robotics report released by the International Federation of Robotics, a Germany-based professional non-profit organization, global industrial robot installations in factories reached 553,052 units, reflecting a 5% year-on-year increase in 2022. Therefore, the rising level of industrial automation is contributing to the growth of the pharmaceutical continuous manufacturing market.

Major companies operating in the pharmaceutical continuous manufacturing market are concentrating on developing advanced equipment, such as continuous manufacturing lines, to strengthen their competitive position. A continuous manufacturing line is a specialized production system in which raw materials are continuously converted into finished products without interruptions. For instance, in January 2023, WuXi STA, a China-based contract research, development, and manufacturing organization, launched a continuous manufacturing line for oral solid dosage forms in Wuxi City, China. This line, which complies with global current Good Manufacturing Practice (cGMP) standards, enhances oral drug development by integrating continuous direct compression equipment for material dispensing, blending, lubrication, tablet compression, and coating. Additionally, Process Analytical Technology (PAT) is incorporated to enable real-time monitoring of blend uniformity, ensuring consistent product quality.

In January 2023, Cambrex Corporation, a US-based contract development and manufacturing organization for pharmaceuticals, acquired Snapdragon Chemistry Inc. for an undisclosed amount. Through this acquisition, Cambrex strengthened its capabilities in active pharmaceutical ingredient process development using continuous flow manufacturing, complementing its recent investments in end-to-end continuous flow process development. Snapdragon Chemistry Inc. is a US-based contract research, development, and chemical manufacturing company specializing in both batch and continuous flow process development for active pharmaceutical ingredients.

Major companies operating in the pharmaceutical continuous manufacturing market are Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV.

Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical continuous manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost and supply chain challenges for the pharmaceutical continuous manufacturing market by increasing prices of imported automation equipment, control software, sensors, and precision machinery essential for integrated continuous systems. These impacts are most pronounced in API manufacturing and final drug product manufacturing segments, with asia-pacific and europe being highly affected due to reliance on cross-border equipment sourcing. Higher tariffs have delayed capital investments for pharmaceutical companies and contract manufacturing organizations, particularly in emerging markets. However, tariffs have also encouraged localized manufacturing, regional supplier development, and increased domestic investments in continuous manufacturing technologies, supporting long-term market resilience.

The pharmaceutical continuous manufacturing market research report is one of a series of new reports that provides pharmaceutical continuous manufacturing market statistics, including pharmaceutical continuous manufacturing industry global market size, regional shares, competitors with a pharmaceutical continuous manufacturing market share, detailed pharmaceutical continuous manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical continuous manufacturing industry. This pharmaceutical continuous manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical continuous manufacturing (PCM) is a production approach in which pharmaceutical products are manufactured from start to finish on a single, uninterrupted production line. It is used to produce active pharmaceutical ingredients through flow-based chemical transformations and multistep syntheses that can operate over extended periods, potentially helping to reduce drug shortages.

The main types of pharmaceutical continuous manufacturing products include integrated continuous systems, controls and software, and semi-continuous systems. An Integrated Continuous System (ICS) is a method of manufacturing pharmaceutical products from beginning to end on one continuous production line. These systems are used in the production of both large-molecule and small-molecule therapeutics and support the manufacture of solid, liquid, and semi-solid formulations. They are applied in areas such as final drug product manufacturing and active pharmaceutical ingredient (API) production and are used by end users including pharmaceutical companies, contract manufacturing organizations, and others.

The pharmaceutical continuous manufacturing market consists of revenues earned by entities by providing manufacturing services such as mixing, granulation, coating, and tablet compression. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical continuous manufacturing market also includes sales of organic PCM and inorganic PCM techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.